UAB researcher awarded first joint AACR- TNBC Foundation Career Development Award focused specifically on triple negative breast cancer.
Elevated PARP1 polymerase in HER2+ breast cancer may confer susceptibility to PARP inhibitor drugs.
Christopher Willey, M.D., Ph.D., receives a crucial ACS research grant to further his novel work on the MARCKS protein in relation to brain cancer.
Researchers at the University of Alabama at Birmingham have identified a strategy that highly aggressive brain tumor cells use to fuel their relentless expansion.
Yang’s research focuses on a new class of drug – PARP inhibitors – that interfere with a cancer cell’s ability to repair DNA damage, hastening cell death.
In this preliminary analysis, the first human study treatment neither built up in organs nor destroyed the bone marrow’s ability to make blood cells.